(Q45695032)

15 December 2017

title

Brain metastases in HER2-positive breast cancer (English)

1 reference

15 December 2017

1 reference

Nancy U Lin

1

1 reference

15 December 2017

publication date

13 February 2013

1 reference

Lancet Oncology Commission

15 December 2017

published in

1 reference

15 December 2017

volume

14

1 reference

15 December 2017

issue

3

1 reference

15 December 2017

page(s)

185-186

1 reference

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

15 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970046-9

7 January 2021

Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970046-9

7 January 2021

Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970046-9

7 January 2021

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970046-9

7 January 2021

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970046-9

7 January 2021

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970046-9

7 January 2021

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970046-9

7 January 2021

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970046-9

7 January 2021

Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970046-9

7 January 2021

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970046-9

7 January 2021

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970046-9

7 January 2021

10.1016/S1470-2045(13)70046-9

Identifiers

DOI

1 reference

15 December 2017

1 reference